Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 121 for “"Sunitinib"”.

  1. Exploring alternative dosing schedules of sunitinib in cancer treatment

    … dosing regimen for the tyrosine kinase inhibitor sunitinib. Tyrosine kinase inhibitors block signals involved in cell growth and differentiation and are often used in the treatment of cancer. Previous phase I research demonstrated that a high-dose intermittent schedule of sunitinib is safe and …

    radboud Repository record for Exploring alternative dosing schedules of sunitinib in cancer treatment (opens in a new tab)

  2. Efecto Cardioprotector de la L-Carnitina en ratas tratadas con Sunitinib

    Ya que el sunitinib no solo es uno de los fármacos más importantes para el tratamiento del carcinoma de células renales y tumores del estroma gastrointestinal resistentes a imatinib, sino que además está siendo evaluado actualmente para una amplia variedad de tumores sólidos -incluyendo cánceres de …

    sevilla Repository record for Efecto Cardioprotector de la L-Carnitina en ratas tratadas con Sunitinib (opens in a new tab)

  3. Oncolytic Vesicular Stomatitis Virus and Sunitinib Combination Therapy for Treating Neuroblastoma

    … have indicated potential. We hypothesized that sunitinib would modulate immune responses to improve oncolytic virus (VSVΔM51) productivity in the tumour and enhance the activity of antitumour immunity activated by VSVΔM51. Using an immunocompetent mouse model of neuroblastoma (neuro-2a), we …

    calgary Repository record for Oncolytic Vesicular Stomatitis Virus and Sunitinib Combination Therapy for Treating Neuroblastoma (opens in a new tab)

  4. Early detection of broken hearts in cancer: Bevacizumab and Sunitinib mediated cardiotoxicity

    Background: Although Bevacizumab (BVZ) and Sunitinib (SNT) prolong survival in cancer patients, an unanticipated side-effect is cardiotoxicity. Early indices of left ventricular (LV) systolic dysfunction would be useful to address the cardiac safety of anti-cancer drugs. Objective: Whether cardiac …

    manitoba Repository record for Early detection of broken hearts in cancer: Bevacizumab and Sunitinib mediated cardiotoxicity (opens in a new tab)

  5. Sunitinib-Induced Cardiotoxicity Exposes Microvascular and Metabolic Derangements In The Failing Heart

    … is the small molecular receptor tyrosine kinase sunitinib. Sunitinib was developed in the early 2000’s as part of a wave of antiangiogenic drugs that target the vascular endothelial growth factor receptors and platelet-derived growth factor receptors. Unfortunately, up to 47% of patients treated …

    uthsc Repository record for Sunitinib-Induced Cardiotoxicity Exposes Microvascular and Metabolic Derangements In The Failing Heart (opens in a new tab)

  6. Enhancing Oncolytic Rhabdovirus Infection With Sunitinib In An IFN Responsive Tumour Model

    … it spreads efficiently through the tumour. Sunitinib (Su), a receptor tyrosine kinase inhibitor, was recently shown to enhance OV infection by inhibiting IFN signaling in tumour cells. We therefore hypothesized that Su might enhance oncolytic rhabdovirus (ORV) infection in tumours. Indeed, …

    calgary Repository record for Enhancing Oncolytic Rhabdovirus Infection With Sunitinib In An IFN Responsive Tumour Model (opens in a new tab)

  7. Sunitinib-loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration

    … ways of delivering anti-VEGF drugs such as Sunitinib to the posterior segment of the eye. In this study, the novel micellar formulation exhibited an average DLS particle size of 132.7 nm with a ZP of -0.159 mV. TEM imaging further confirmed the nanoscopic size of the micelles with sizes …

    usf Repository record for Sunitinib-loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration (opens in a new tab)

  8. Der Einfluss des Multityrosinkinaseinhibitors Sunitinib auf die Proliferation und Steroidbiosynthese von Nebennierenkarzinomzellen in vitro

    … Onkologie einen wachsenden Stellenwert ein. Sunitinib wirkt als Multityrosinkinaseinhibitor einerseits antiangiogenetisch, andererseits auch direkt antiproliferativ auf Tumorzellen. Im Tierversuch sind unter Sunitinib adrenotoxische Wirkungen beschrieben. Für das Nebennierenkarzinom, eine …

    wurz-thes Repository record for Der Einfluss des Multityrosinkinaseinhibitors Sunitinib auf die Proliferation und Steroidbiosynthese von Nebennierenkarzinomzellen in vitro (opens in a new tab)

  9. IMMUNOLOGICAL SIGNATURE IN NAÏVE AND SUNITINIB-TREATED SOFT TISSUE SARCOMA PATIENTS: ROLE OF MYELOID CELLS

    … anti-angiogenic drugs (e.g. sunitinib), have been described to influence tumor-host interactions. Sunitinib is currently in use at our Institute for the treatment of progressive, advanced soft tissue sarcomas (STS) of different histology. However, the systemic and local immune …

    milano Repository record for IMMUNOLOGICAL SIGNATURE IN NAÏVE AND SUNITINIB-TREATED SOFT TISSUE SARCOMA PATIENTS: ROLE OF MYELOID CELLS (opens in a new tab)

  10. Evaluación del daño vascular tras el tratamiento con Sunitinib: disfunción endotelial y mecanismos patogénicos implicados

    Sunitinib (Su) is an orally active multitarget tyrosine kin ase inhibitor with antiangiogenic and antineoplastic effects. Su is the first line choice for metastatic renal cell carcinoma treatment ( and the second line one for gastrointestinal stromal tumours (GISTs) and pancreatic neuroendocrine …

    sevilla Repository record for Evaluación del daño vascular tras el tratamiento con Sunitinib: disfunción endotelial y mecanismos patogénicos implicados (opens in a new tab)

  11. Enhancing the Anti-Tumour Immune Response of Reovirus with Sunitinib for the Treatment of Multiple Myeloma

    … (RV) as monotherapy and in combination with sunitinib (SUT) – a multi-tyrosine kinase inhibitor - for the treatment of MM. We utilized a syngeneic, immunocompetent, transplantable model of MM (Vk*MYC) for our lines of experimentation. Although our studies demonstrated that the addition of SUT …

    calgary Repository record for Enhancing the Anti-Tumour Immune Response of Reovirus with Sunitinib for the Treatment of Multiple Myeloma (opens in a new tab)

  12. Oncolytic Reovirus Combined with Sunitinib as a Novel Multi-Mechanistic Treatment Strategy for Renal Cell Carcinoma

    … as a monotherapy and in combination with sunitinib, a first line mRCC agent and multi-tyrosine kinase inhibitor, for the treatment of RCC. To assess this, studies employing a panel of RCC cell lines, as well as a syngeneic immunocompetent murine model of RCC were utilized. Collectively, …

    calgary Repository record for Oncolytic Reovirus Combined with Sunitinib as a Novel Multi-Mechanistic Treatment Strategy for Renal Cell Carcinoma (opens in a new tab)

  13. The cardioprotective role of renin-angiotensin system antagonists in the prevention of Bevacizumab and Sunitinib mediated cardiotoxicity

    Background: Targeted agents Bevacizumab and Sunitinib are associated with an increased risk of cardiovascular complications in colorectal and renal cancer settings, respectively. Objective: To elucidate whether renin-angiotensin system (RAS) antagonists can prevent Bevacizumab and Sunitinib …

    manitoba Repository record for The cardioprotective role of renin-angiotensin system antagonists in the prevention of Bevacizumab and Sunitinib mediated cardiotoxicity (opens in a new tab)

  14. Developing A Preclinical Model Of Human Sunitinib Cardiotoxicity To Assess The Role Of Mechanical Loading Using Engineered Cardiac Microtissues

    ABSTRACT DEVELOPING A PRECLINICAL MODEL OF HUMAN SUNITINIB CARDIOTOXICITY TO ASSESS THE ROLE OF MECHANICAL LOADING USING ENGINEERED CARDIAC MICROTISSUES Rachel Elizabeth Truitt Kenneth B. Margulies, MD Sunitinib, a multi-targeted oral tyrosine kinase inhibitor used to treat many solid tumors, has …

    penn Repository record for Developing A Preclinical Model Of Human Sunitinib Cardiotoxicity To Assess The Role Of Mechanical Loading Using Engineered Cardiac Microtissues (opens in a new tab)

  15. Präventive Behandlung von Knochenmetastasen des Mammakarzinoms durch Kombinationstherapie mit taxanhaltiger Chemotherapie, Bisphosphonaten und dem Angiogenesehemmer SU11248 (Sunitinib) im Tiermodell

    … die präventive Wirkung des Angioge-nesehemmers Sunitinib (Sutent(R), Pfizer Pharma GmbH, Berlin) als alleiniges Medikament und als Teil einer kombinierten Therapie mit dem Bisphosphonat Zoledronat (Zometa(R), Novartis Pharma GmbH, Nürnberg) oder dem Taxan Docetaxel (Taxotere(R), Sanofi Aventis …

    cau-kiel Repository record for Präventive Behandlung von Knochenmetastasen des Mammakarzinoms durch Kombinationstherapie mit taxanhaltiger Chemotherapie, Bisphosphonaten und dem Angiogenesehemmer SU11248 (Sunitinib) im Tiermodell (opens in a new tab)

  16. Potenziell prädiktive Biomarker für das Ansprechen auf Sunitinib und deren Assoziation mit dem Überleben von Patienten mit metastasiertem Nierenzellkarzinom

    … sowie die Vorherage für das Ansprechen auf eine Sunitinib-Therapie beim metastasierten NZK zu identifizieren. Für das Prognosemodell am lokal begrenzten NZK konnten auf mRNA-Ebene signifikante Assoziationen der Marker HIF-2α, VEGFR3 und sVEGFR1 mit dem PFS, TSS und OS der Patienten identifiziert …

    qucosa-diss

Page 1 of 7